, UNF
--/--/-- --:--:-- Back to news
| Date: | --/--/-- --:--:-- |
| Event Id: | E5DUE3OZQ |
| Action Type: | ACQUISITION |
| Action Status: | ANNOUNCED |
| Acquirer Symbol: | |
| Target Symbol: | UNF |
| Updated: | --/--/-- --:--:-- |
| Purchase Price Per Share: | 310 |
| Price Per Share Currency: | USD |
| News References: | https://www.globenewswire.com/news-release/2026/06/12/3311010/33488/en/unifirst-shareholders-approve-transaction-with-cintas.html |
Action Notes
Cintas Corporation today announced that it submitted a proposal to the Board of Directors of UniFirst Corporation to acquire all outstanding common and class B shares of UniFirst for $275.00 per share (the "Proposal") in cash. The Proposal, which was delivered to the UniFirst Board on December 12, 2025, implies a total value for UniFirst of approximately $5.2 billion and offers UniFirst shareholders a 64% premium to UniFirst's ninety-day average closing price as of December 11, 2025. Cintas expects to have limited and specific confirmatory due diligence requirements, customary for a public company transaction of this nature. Completion of the contemplated transaction is contingent upon reaching a definitive agreement and would be subject to the satisfaction of customary closing conditions, including receipt of UniFirst shareholder approval.Cintas Corporation and UniFirst Corporation today announced that they have entered into a definitive agreement under which Cintas will acquire UniFirst for $310.00 per share in cash and stock, representing an enterprise value of approximately $5.5 billion.1 The transaction is expected to close in the second half of calendar 2026, subject to customary closing conditions, approval by UniFirst shareholders and the receipt of certain regulatory approvals.5/11 UNF shareholders will vote on merger at special meeting June 11,2026.UniFirst Shareholders Approve Transaction with Cintas .The Company continues to expect the transaction to close in the second half of calendar 2026, subject to customary closing conditions and the receipt of certain regulatory approvals.